comprehensive -WSS

comprehensive

author：explore 2025-09-29 22:48:24 - browse：28

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Medicaid rebukes states for mistakenly disenrolling children

Wikipedia

explore

WSS

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

As the dark side of IVF slowly comes into focus, even more transparency is needed

What drug price negotiations mean for Medicare Part D

'The boss' wants server deleted: New allegations emerge in Trump indictment

Why Novartis is changing the name of its research labs

Advances in CAR

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How one medical school became remarkably diverse

As the dark side of IVF slowly comes into focus, even more transparency is needed

Hepatitis C has a cure — but many Americans still lack access to it

How to fix cancer clinical trials' diversity problem

Continuity nursing helped my family in our darkest PICU moments

Crinetics acromegaly drug succeeds in late

Continuity nursing helped my family in our darkest PICU moments

A new House health package & hospitals’ new site

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Humana sues Biden admin over Medicare Advantage audit rule

explore

Will biotech layoffs continue through 2023?

Ethical issues complicate the benefits of medical crowdfunding

AstraZeneca chief proposes a novel edit to the drug pricing bill

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Amazon on where the company's health care bets are headed next

hotspot

Wikipedia

explore

knowledge